DGAP-News: Newron Pharmaceuticals S.p.A. / Key word(s): AGM/EGM Newron announces AGM 2021 result 2021-04-13 / 12:00 The issuer is solely responsible for the content of this announcement. =---------------------------------------------------------------------------------------------------------------------- Newron announces AGM 2021 result Milan, Italy - April 13, 2021 - Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, announced that its shareholders approved the sole motion on the agenda of the AGM 2021 held today, being the approval of the Company's balance sheet as of 31 December 2020 (including related and consequent resolutions). About Newron Pharmaceuticals Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago^(R)/safinamide has received marketing authorization for the treatment of Parkinson's disease in the European Union, Switzerland, the USA, Australia, Canada, Brazil, Colombia, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron's Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia. For more information, please visit: www.newron.com For more information Newron Stefan Weber - CEO +39 02 6103 46 26 pr@newron.com UK/Europe Simon Conway/ Natalie Garland-Collins, FTI Consulting SCnewron@fticonsulting.com Switzerland Valentin Handschin, IRF Reputation +41 43 244 81 54 handschin@irf-reputation.ch Germany/Europe Anne Hennecke/Caroline Bergmann, MC Services +49 211 52925220 newron@mc-services.eu USA Paul Sagan, LaVoieHealthScience +1 617 374 8800, Ext. 112 psagan@lavoiehealthscience.com =---------------------------------------------------------------------------------------------------------------------- 2021-04-13 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de =----------------------------------------------------------------------------------------------------------------------
1184059 2021-04-13
(END) Dow Jones Newswires
April 13, 2021 06:00 ET (10:00 GMT)